Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 394

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 394
---
, consisting of over 300 compounds, bridges the present to the future treatment of sleep disorders as well as other neuro -degenerativedisorders. Orexin receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological processes of neurological diseases such as obesity, narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer’s disease. These new compounds, in addition to NLS’s current pipeline, including Mazindol ER for the treatment of narcolepsy, NLS -4focused on idiopathic hypersomnia, long -COVIDand chronic fatigue syndrome, and NLS -11, addressing Kleine -LevinSyndrome and neurodegenerative diseases, will further complement and strengthen NLS’s sleep franchise. NLS will be uniquely positioned to hold the key to unlock the challenges associated with rare sleep disorders now and in the future. 192 In addition, NLS initiated a comprehensive exploration of new opportunities that align with NLS’s core values and strengths, with the goal of diversifying NLS’s revenue streams, mitigating risks and creating lasting value for NLS’s stakeholders. As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including strategic partnerships, out licensing assets of the Company, and other future strategic actions. Several strategic partnerships discussions are currently under way and in advanced stages of negotiations. As always, NLS continued to approach the sleep medicine market from a holistic perspective. According to “Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments — Forecast to 2030” the global sleep medicine market is estimated to increase to more than $100 billion by 2030, with narcolepsy accounting for over $6 billion by 2030. License Agreements Pegasus Advanced Research SAS License Agreement In February 2015, Pegasus Advanced Research, then named NeuroLife -SciencesSAS, or Pegasus, a company owned by certain of NLS’s founders, who are also shareholders, including Eric Konofal, Eric -JeanDesbois, Bruno Figadere and NLS’s Chief Executive Officer, Alexander Zwyer, or the Pegasus Founders, entered into a license agreement with AP -HP, or the AP -HPLicense Agreement, to obtain a worldwide, sub -licensablelicense, covering four different compounds, which included the use of m